The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of h...
AbstractBackgroundAfter orthotopic liver transplantation (OLT) in chronic hepatitis B (HBV), adequat...
WOS: 000385758800005PubMed ID: 27409074BackgroundThe aim of this study was to determine the long-ter...
<div><p>Introduction</p><p>Prophylactic administration of hepatitis B immunoglobulin (HBIG) and nucl...
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplan...
Despite universal vaccination and antiviral therapies being available for decades, chronic hepatitis...
Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates, such as entecavir...
Without any treatment, the prognosis of hepatitis B in liver transplant recipients is very poor. So...
Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B vi...
AIM: The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has ...
Hepatitis B often progresses to decompensated liver cirrhosis requiring orthotopic liver transplanta...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
AIM: The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has i...
WOS: 000260485500015PubMed ID: 18847315Post-transplant hepatitis B virus (HBV) recurrence prophylaxi...
The combination of hepatitis B immunoglobulin (HBIG) and antivirals (nucleos[t]ide analogs) has exte...
AbstractBackgroundAfter orthotopic liver transplantation (OLT) in chronic hepatitis B (HBV), adequat...
WOS: 000385758800005PubMed ID: 27409074BackgroundThe aim of this study was to determine the long-ter...
<div><p>Introduction</p><p>Prophylactic administration of hepatitis B immunoglobulin (HBIG) and nucl...
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplan...
Despite universal vaccination and antiviral therapies being available for decades, chronic hepatitis...
Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates, such as entecavir...
Without any treatment, the prognosis of hepatitis B in liver transplant recipients is very poor. So...
Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B vi...
AIM: The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has ...
Hepatitis B often progresses to decompensated liver cirrhosis requiring orthotopic liver transplanta...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis...
AIM: The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has i...
WOS: 000260485500015PubMed ID: 18847315Post-transplant hepatitis B virus (HBV) recurrence prophylaxi...
The combination of hepatitis B immunoglobulin (HBIG) and antivirals (nucleos[t]ide analogs) has exte...
AbstractBackgroundAfter orthotopic liver transplantation (OLT) in chronic hepatitis B (HBV), adequat...
WOS: 000385758800005PubMed ID: 27409074BackgroundThe aim of this study was to determine the long-ter...
<div><p>Introduction</p><p>Prophylactic administration of hepatitis B immunoglobulin (HBIG) and nucl...